ReviewCurrent neurology and neuroscience reports2015
CGRP mechanism antagonists and migraine management.
Review in Current neurology and neuroscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients.Biomedicines · 2024Article
- Practical supplements for prevention and management of migraine attacks: a narrative review.Frontiers in nutrition · 2024Review
- Article
- Current concepts in migraine and their relevance to pregnancy.Obstetric medicine · 2018Review
- Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.British journal of pharmacology · 2018Review
- Secondary traumatic stress increases expression of proteins implicated in peripheral and central sensitization of trigeminal neurons.Brain research · 2018Article
- Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.Drugs · 2018Review
- Migraine with prolonged aura: phenotype and treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2018Review
- Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.British journal of pharmacology · 2018Review
- Neuropeptides and ATP signaling in the trigeminal ganglion.The Japanese dental science review · 2017Review
- Premonitory Symptoms of Migraine in Childhood and Adolescence.Current pain and headache reports · 2017Review
- Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review.Frontiers in neurology · 2017Review
- Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice.Journal of neuropathology and experimental neurology · 2016Article
- New players in the preventive treatment of migraine.BMC medicine · 2015Review
- Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the trigeminovascular nociceptive system widely from the trigeminal ganglion to second-order and third-order neurons and in regulatory areas in the brainstem. Studies have shown CGRP is released during severe migraine attacks and the reversal of the attack with effective triptan treatment normalizes those levels. CGRP administration triggers migraine in patients, and CGRP receptor antagonists have been shown to abort migraine. Here, we review the current state of CGRP mechanism antagonist therapy as its research and development is increasing in migraine therapeutics. We discuss several recent trials, highlighting the evidence base behind these novel drugs, and their potential future contribution to migraine management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.